The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle
Open accessAbstract
Mavacamten, formerly known as MYK-461 is a recently discovered novel small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent heritable cardiovascular disorders. Studies on isolated cells and muscle fibers as well as intact animals have shown that mavacamten inhibits sarcomere force production, thereby reducing cardiac contractility. Initial mechanistic studies have suggested that mavacamten primarily reduces the steady-state ATPase activity by inhibiting the rate of phosphate release of β-cardiac myosin-S1, but the molecular mechanism of action of mavacamten has not been described. Here we used steady-state and presteady-state kinetic analyses to investigate the mechanism of action of mavacamten. Transient kinetic analyses revealed that mavacamten modulates multiple steps of the myosin chemomechanical cycle. In addition to decreasing the rate-limiting step of the cycle (phosphate release), mavacamten reduced the number of myosin-S1 heads that can interact with the actin thin filament during transition from the weakly to the strongly bound state without affecting the intrinsic rate. Mavacamten also decreased the rate of myosin binding to actin in the ADP-bound state and the ADP-release rate from myosin-S1 alone. We, therefore, conclude that mavacamten acts on multiple stages of the myosin chemomechanical cycle. Although the primary mechanism of mavacamten-mediated inhibition of cardiac myosin is the decrease of phosphate release from β-cardiac myosin-S1, a secondary mechanism decreases the number of actin-binding heads transitioning from the weakly to the strongly bound state, which occurs before phosphate release and may provide an additional method to modulate myosin function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of disease: hypertrophic cardiomyopathy
Frey, N., Luedde, M., & Katus, H. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.159 · Cited by 235
CUDA, G., FANANAPAZIR, L., EPSTEIN, N. D., & SELLERS, J. R. (1997) · Journal of Muscle Research & Cell Motility · doi:10.1023/a:1018613907574 · Cited by 137
Cited by
Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Anderson, R. L., Trivedi, D. V., Sarkar, S. S., Henze, M., Ma, W., Gong, H., Rogers, C. S., Gorham, J. M., Wong, F. L., Morck, M. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809540115 · Cited by 405
Self-citationEvaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Ho, C. Y., Mealiffe, M. E., Bach, R. G., Bhattacharya, M., Choudhury, L., Edelberg, J. M., Hegde, S. M., Jacoby, D., Lakdawala, N. K., Lester, S. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.064 · Cited by 355
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial
Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A., Wang, A., Zhang, D., Lambing, J., Lee, J., Semigran, M., & Sehnert, A. J. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3016 · Cited by 303
Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies
Yotti, R., Seidman, C. E., & Seidman, J. G. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015306 · Cited by 168
Metadata
- Authors
- Kawas, R. F., Anderson, R. L., Ingle, S. R. B., Song, Y., Sran, A. S., & Rodriguez, H. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 292
- Issue
- 40
- Pages
- 16571-16577
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2747734729
- Cited by
- 222
- References
- 2
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. https://app.cochat.ai/papers/10.1074/jbc.m117.776815
- The paper
- Kawas, R. F., Anderson, R. L., Ingle, S. R. B., Song, Y., Sran, A. S., & Rodriguez, H. M. (2017). A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m117.776815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.